Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 10(1): 6201, 2020 04 10.
Artigo em Inglês | MEDLINE | ID: mdl-32277089

RESUMO

Broadly neutralising antibodies (bNAbs) against human immunodeficiency virus type 1 (HIV-1), such as CAP256-VRC26 are being developed for HIV prevention and treatment. These Abs carry a unique but crucial post-translational modification (PTM), namely O-sulfated tyrosine in the heavy chain complementarity determining region (CDR) H3 loop. Several studies have demonstrated that plants are suitable hosts for the generation of highly active anti-HIV-1 antibodies with the potential to engineer PTMs. Here we report the expression and characterisation of CAP256-VRC26 bNAbs with posttranslational modifications (PTM). Two variants, CAP256-VRC26 (08 and 09) were expressed in glycoengineered Nicotiana benthamiana plants. By in planta co-expression of tyrosyl protein sulfotransferase 1, we installed O-sulfated tyrosine in CDR H3 of both bNAbs. These exhibited similar structural folding to the mammalian cell produced bNAbs, but non-sulfated versions showed loss of neutralisation breadth and potency. In contrast, tyrosine sulfated versions displayed equivalent neutralising activity to mammalian produced antibodies retaining exceptional potency against some subtype C viruses. Together, the data demonstrate the enormous potential of plant-based systems for multiple posttranslational engineering and production of fully active bNAbs for application in passive immunisation or as an alternative for current HIV/AIDS antiretroviral therapy regimens.


Assuntos
Anticorpos Neutralizantes/genética , Anticorpos Anti-HIV/genética , Nicotiana/genética , Plantas Geneticamente Modificadas/genética , Anticorpos Neutralizantes/imunologia , Biotecnologia , Engenharia Genética , Anticorpos Anti-HIV/imunologia , Infecções por HIV/imunologia , Infecções por HIV/terapia , HIV-1/genética , HIV-1/imunologia , Humanos , Plantas Geneticamente Modificadas/imunologia , Engenharia de Proteínas , Processamento de Proteína Pós-Traducional , Nicotiana/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...